
Jogarao V Gobburu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6390372/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Future of pharmacometrics: Predictive healthcare analytics. British Journal of Clinical Pharmacology, 2022, 88, 1427-1429.	2.4	4
2	Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children. JCI Insight, 2022, 7, .	5.0	12
3	Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. Journal of Clinical Pharmacology, 2022, , .	2.0	1
4	Interspecies Comparison and Radiation Effect on Pharmacokinetics of BIO 300, a Nanosuspension of Genistein, after Different Routes of Administration in Mice and Non-Human Primates. Radiation Research, 2022, 197, .	1.5	7
5	Accelerating the Availability of Medications to Pediatric Patients by Optimizing the Use of Extrapolation of Efficacy. Therapeutic Innovation and Regulatory Science, 2022, 56, 873-882.	1.6	3
6	Development and Use of an Ex-Vivo In-Vivo Correlation to Predict Antiepileptic Drug Clearance in Patients Undergoing Continuous Renal Replacement Therapy. Pharmaceutical Research, 2022, , .	3.5	1
7	Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. American Journal of Obstetrics and Gynecology, 2021, 225, 85.e1-85.e11.	1.3	24
8	Exposureâ€Response Analysis to Assess the Concentrationâ€QTc Relationship of Psilocybin/Psilocin. Clinical Pharmacology in Drug Development, 2021, 10, 78-85.	1.6	19
9	A Pharmacokinetic and Pharmacodynamic Investigation of an ε-Aminocaproic Acid Regimen Designed for Cardiac Surgery With Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 406-417.	1.3	7
10	Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery. Journal of Thrombosis and Haemostasis, 2021, 19, 221-232.	3.8	23
11	Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery. British Journal of Clinical Pharmacology, 2021, 87, 3531-3541.	2.4	15
12	A prospective, realâ€world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADREâ€02). British Journal of Clinical Pharmacology, 2021, 87, 4375-4385.	2.4	2
13	Understanding the Role of Pharmacometricsâ€Based Clinical Decision Support Systems in Pediatric Patient Management: A Case Study Using Lyv Software. Journal of Clinical Pharmacology, 2021, 61, S125-S132.	2.0	4
14	Characterization of Drugâ€Drug Interactions on the Pharmacokinetic Disposition of Busulfan in Pediatric Patients during Hematopoietic Stem Cell Transplantation Conditioning. British Journal of Clinical Pharmacology, 2021, , .	2.4	3
15	Dynamic PET-facilitated modeling and high-dose rifampin regimens for <i>Staphylococcus aureus</i> orthopedic implant–associated infections. Science Translational Medicine, 2021, 13, eabl6851.	12.4	16
16	125. Dynamic PET facilitated Pharmacokinetic Modeling and High-dose Rifampin Regimens for <i>Staphylococcus aureus</i> Orthopedic Implant Associated Infections: Bench to Bedside. Open Forum Infectious Diseases, 2021, 8, S75-S76.	0.9	0
17	An Innovative Diseaseâ€Drugâ€Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate. Clinical and Translational Science, 2020, 13, 88-97.	3.1	5
18	Dosage Regimens for Meropenem in Children with Pseudomonas Infections Do Not Meet Serum Concentration Targets. Clinical and Translational Science, 2020, 13, 301-308.	3.1	9

Jogarao V Gobburu

#	Article	IF	CITATIONS
19	Personalized Management of Chemotherapyâ€Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). Journal of Clinical Pharmacology, 2020, 60, 444-452.	2.0	7
20	Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nature Medicine, 2020, 26, 529-534.	30.7	87
21	MID3: Mission Impossible or Modelâ€Informed Drug Discovery and Development? Pointâ€Counterpoint Discussions on Key Challenges. Clinical Pharmacology and Therapeutics, 2020, 107, 762-772.	4.7	12
22	A Practiceâ€Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADREâ€01). Clinical and Translational Science, 2020, 13, 950-959.	3.1	8
23	Population Pharmacokinetic Modeling of Gentamicin in Pediatrics. Journal of Clinical Pharmacology, 2019, 59, 1584-1596.	2.0	11
24	Cancer Clinical Investigators Should Converge with Pharmacometricians. Clinical Cancer Research, 2019, 25, 5182-5184.	7.0	3
25	Clinical Pharmacologyâ€Driven Translational Research to Optimize Bedside Therapeutics of Sotalol Therapy. Clinical and Translational Science, 2019, 12, 648-656.	3.1	4
26	Could Postnatal Age–Related Uridine Diphosphate Glucuronic Acid Be a Rate‣imiting Factor in the Metabolism of Morphine During the First Week of Life?. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 469-477.	2.5	4
27	Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 181-191.	1.3	13
28	Integrated Model to Describe Morphine Pharmacokinetics in Humans. Journal of Clinical Pharmacology, 2019, 59, 1070-1077.	2.0	7
29	Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemotherapy and Pharmacology, 2019, 83, 319-328.	2.3	9
30	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation, 2019, 129, 616-630.	8.2	94
31	Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposureâ€FLT3 Relationship. Clinical and Translational Science, 2018, 11, 435-443.	3.1	15
32	Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 10-18.	1.3	18
33	A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4. Journal of Pharmaceutical Sciences, 2018, 107, 942-948.	3.3	4
34	Noninvasive ¹¹ C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. Science Translational Medicine, 2018, 10, .	12.4	73
35	Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. British Journal of Clinical Pharmacology, 2017, 83, 1688-1700.	2.4	7
36	Exposureâ€response analysis after subcutaneous administration of RBPâ€7000, a onceâ€aâ€month longâ€acting Atrigel formulation of risperidone. British Journal of Clinical Pharmacology, 2017, 83, 1476-1498.	2.4	18

#	Article	IF	CITATIONS
37	Parentâ€Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABTâ€888), a PARP Inhibitor, in Patients With <i>BRCA 1/2</i> ‑Mutated Cancer or PARP‣ensitive Tumor Types. Journal of Clinical Pharmacology, 2017, 57, 977-987.	2.0	17
38	Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS Journal, 2017, 19, 1411-1423.	4.4	7
39	Bayesian Forecasting Tool to Predict the Need for Antidote in Acute Acetaminophen Overdose. Pharmacotherapy, 2017, 37, 916-926.	2.6	7
40	Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies. Clinical Cancer Research, 2017, 23, 6421-6429.	7.0	4
41	Allometry Is a Reasonable Choice in Pediatric Drug Development. Journal of Clinical Pharmacology, 2017, 57, 469-475.	2.0	46
42	Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. Journal of Clinical Pharmacology, 2017, 57, 247-254.	2.0	5
43	Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium. Journal of Clinical Pharmacology, 2016, 56, 1009-1018.	2.0	36
44	Pharmacometricsâ€guided drug development of antihyperhidrosis agents. Journal of Clinical Pharmacology, 2015, 55, 1256-1267.	2.0	9
45	Drug Development and Potential Regulatory Paths for Insulin Biosimilars. Journal of Diabetes Science and Technology, 2014, 8, 14-19.	2.2	6
46	Genetics-Based Pediatric Warfarin Dosage Regimen Derived Using Pharmacometric Bridging. Journal of Pediatric Pharmacology and Therapeutics, 2013, 18, 209-219.	0.5	15
47	Don't Get Boxed In: Commentary on the Visual Inspection Practices to Assess Exposureâ€Response Relationships From Binary Clinical Variables. Journal of Clinical Pharmacology, 2012, 52, 1912-1917.	2.0	6
48	Pharmacokinetic and Pharmacodynamic Basis for Effective Argatroban Dosing in Pediatrics. Journal of Clinical Pharmacology, 2011, 51, 19-28.	2.0	59
49	Pharmacometrics 2020. Journal of Clinical Pharmacology, 2010, 50, 151S-157S.	2.0	41
50	Population Pharmacokinetic-Based Dosing of Intravenous Busulfan in Pediatric Patients. Journal of Clinical Pharmacology, 2007, 47, 101-111.	2.0	84
51	Optimising piperacillin/tazobactam dosing in paediatrics. International Journal of Antimicrobial Agents, 2007, 30, 320-324.	2.5	30
52	Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 1999, 16, 1412-1416.	3.5	26
53	Pharmacometrics Applications to Pediatric Trials. , 0, , 332-341.		1
54	Population Pharmacokinetics of Vancomycin in Pregnant Women. Frontiers in Pharmacology, 0, 13, .	3.5	4